Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Endocrine-Based Strategies After CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer
jRCT1051230031Phase 2Recruiting
- Sponsor
- Sysmex
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of everolimus in breast cancer (2 arms), sponsored by Sysmex. Primary endpoint: Time to failure of strategy (TFS). Started Jun 2023; status: recruiting.
02
Drugs
everolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT1051230031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051230031.